A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Personalis develops, markets, and sells advanced cancer genomic testing services. Our testing services are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. Our testing services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and clinical trials. We also provide whole exome sequencing services for other diagnostic companies and whole genome sequencing services for population sequencing initiatives. We perform our testing services in a large-scale, high-quality, Clinical Laboratory Improvement Amendments of 1988 ("CLIA") certified and College of American Pathologists (“CAP”) accredited, laboratory located in our 100,000 square foot headquarters in Fremont, California. We were incorporated under the laws of the state of Delaware in 2011 under the name Personalis, Inc.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 70M | 70M | 85M | 73M | 65M | 85M |
| Net Income | -81M | -81M | -81M | -108M | -113M | -65M |
| EPS | $-0.91 | $-0.91 | $-1.37 | $-2.25 | $-2.48 | $-1.49 |
| Free Cash Flow | -79M | -79M | -47M | -67M | -120M | -82M |
| ROIC | -50.8% | -31.1% | -40.0% | -83.7% | -51.9% | -21.0% |
| Gross Margin | 22.7% | 22.7% | 31.7% | 24.8% | 20.5% | 37.0% |
| Debt/Equity | 0.00 | 0.28 | 0.33 | 0.74 | 0.34 | 0.28 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -88M | -88M | -68M | -110M | -116M | -65M |
| Operating Margin | -126.4% | -126.4% | -80.7% | -149.6% | -177.6% | -76.4% |
| ROE | -31.1% | -35.0% | -40.0% | -83.7% | -51.9% | -21.0% |
| Shares Outstanding | 89M | 89M | 59M | 48M | 46M | 44M |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 38M | 65M | 79M | 85M | 65M | 73M | 85M | 70M | 70M |
| Gross Margin | 31.3% | 33.9% | 25.6% | 37.0% | 20.5% | 24.8% | 31.7% | 22.7% | 22.7% |
| R&D | 14M | 22M | 29M | 49M | 65M | 65M | 49M | 50M | 50M |
| SG&A | 11M | 22M | 34M | 48M | 64M | 50M | 46M | 54M | 54M |
| EBIT | -14M | -22M | -42M | -65M | -116M | -110M | -68M | -88M | -88M |
| Op. Margin | -36.5% | -34.4% | -53.6% | -76.4% | -177.6% | -149.6% | -80.7% | -126.4% | -126.4% |
| Net Income | -20M | -25M | -41M | -65M | -113M | -108M | -81M | -81M | -81M |
| Net Margin | -52.6% | -38.5% | -52.5% | -76.3% | -174.2% | -147.4% | -96.1% | -116.7% | -116.7% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 8.1M | 0 | 0 | 0 |
| Returns on Capital | |||||||||
| ROIC | -33.0% | -23.5% | -21.2% | -21.0% | -51.9% | -83.7% | -40.0% | -31.1% | -50.8% |
| ROE | N/A | -23.5% | -21.2% | -21.0% | -51.9% | -83.7% | -40.0% | -35.0% | -31.1% |
| ROA | -47.7% | -15.9% | -16.9% | -16.4% | -38.7% | -48.1% | -30.1% | -26.9% | -24.3% |
| Cash Flow | |||||||||
| Op. Cash Flow | 5.6M | -18M | -43M | -71M | -70M | -56M | -45M | -75M | -75M |
| Free Cash Flow | -2.3M | -26M | -46M | -82M | -120M | -67M | -47M | -79M | -79M |
| Owner Earnings | 1.2M | -28M | -57M | -91M | -98M | -82M | -67M | -94M | -94M |
| CapEx | 7.9M | 8.4M | 3.2M | 11M | 50M | 11M | 1.6M | 4.5M | 4.5M |
| Maint. CapEx | 3.1M | 4.7M | 5.8M | 6.0M | 8.4M | 11M | 11M | 10M | 10M |
| Growth CapEx | 4.8M | 3.6M | 0 | 5.1M | 41M | 0 | 0 | 0 | 0 |
| D&A | 3.1M | 4.7M | 5.8M | 6.0M | 8.4M | 11M | 11M | 10M | 10M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 1.3M | 4.9M | 8.2M | 14M | 19M | 14M | 11M | 9.4M | 9.4M |
| Debt Repayment | 645K | 25M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||
| Net Debt | -34M | -118M | N/A | N/A | N/A | N/A | N/A | N/A | -124M |
| Cash & Equiv. | 20M | 55M | 69M | 106M | 89M | 57M | 91M | 124M | 124M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | -0.05 | 0.09 | 0.26 | 0.28 | 0.34 | 0.74 | 0.33 | 0.28 | 0.00 |
| Interest Coverage | -7.3 | -19.8 | -21073.0 | -355.2 | -574.8 | -999.4 | -2844.5 | -429.5 | -429.5 |
| Equity | -106M | 107M | 195M | 310M | 218M | 129M | 203M | 261M | 261M |
| Total Assets | 42M | 157M | 245M | 397M | 293M | 225M | 270M | 334M | 334M |
| Total Liabilities | 148M | 51M | 50M | 86M | 75M | 96M | 67M | 73M | 73M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -116M | -141M | -182M | -247M | -360M | -469M | -550M | -631M | -631M |
| Working Capital | -28M | 90M | 180M | 287M | 167M | 100M | 172M | 228M | 228M |
| Current Assets | 30M | 140M | 221M | 318M | 200M | 147M | 203M | 268M | 268M |
| Current Liabilities | 58M | 50M | 41M | 31M | 33M | 47M | 31M | 40M | 40M |
| Per Share Data | |||||||||
| EPS | -6.49 | -1.39 | -1.20 | -1.49 | -2.48 | -2.25 | -1.37 | -0.91 | -0.91 |
| Owner EPS | 0.04 | -0.63 | -1.65 | -2.08 | -2.15 | -1.70 | -1.13 | -1.06 | -1.06 |
| Book Value | -3.38 | 2.44 | 5.67 | 7.09 | 4.77 | 2.69 | 3.42 | 2.92 | 2.92 |
| Cash Flow/Share | 0.18 | -0.41 | -1.24 | -1.62 | -1.54 | -1.17 | -0.76 | -0.84 | -0.80 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 31.5M | 43.7M | 34.4M | 43.8M | 45.7M | 48.1M | 59.3M | 89.3M | 89.3M |
| Valuation | |||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -6.9 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 4.0 | 7.3 | 1.9 | 0.4 | 0.9 | 1.7 | 2.8 | 2.2 |
| Price/Sales | N/A | 10.3 | 7.6 | 12.2 | 3.9 | 1.3 | 2.0 | 7.6 | 8.1 |
| FCF Yield | N/A | -6.3% | -3.2% | -13.9% | -146.1% | -59.4% | -13.4% | -10.9% | -14.1% |
| Market Cap | N/A | 423M | 1.4B | 588M | 82M | 113M | 348M | 727M | 564M |
| Avg. Price | N/A | 15.44 | 17.42 | 23.92 | 5.58 | 2.03 | 2.91 | 5.96 | 6.31 |
| Year-End Price | N/A | 9.68 | 41.42 | 13.43 | 1.80 | 2.35 | 5.87 | 8.14 | 6.31 |
Personalis, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 27.3%.
Personalis, Inc. (PSNL) has a 5-year average return on invested capital (ROIC) of -45.6%. This is below average and may indicate limited pricing power.
Personalis, Inc. (PSNL) has a market capitalization of $564M. It is classified as a small-cap stock.
Personalis, Inc. (PSNL) does not currently pay a regular dividend.
Personalis, Inc. (PSNL) operates in the Services-Medical Laboratories industry, within the Healthcare sector.
Personalis, Inc. (PSNL) reported annual revenue of $70 million in its most recent fiscal year, based on SEC EDGAR filings.
Personalis, Inc. (PSNL) has a net profit margin of -116.7%. The company is currently unprofitable.
Personalis, Inc. (PSNL) generated $-79 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Personalis, Inc. (PSNL) has a debt-to-equity ratio of 0.28. This indicates a conservatively financed balance sheet.
Personalis, Inc. (PSNL) reported earnings per share (EPS) of $-0.91 in its most recent fiscal year.
Personalis, Inc. (PSNL) has a return on equity (ROE) of -35.0%. A negative ROE may indicate losses or negative equity.
Personalis, Inc. (PSNL) has a 5-year average gross margin of 27.3%. This lower margin is typical of capital-intensive or commodity businesses.
The Ledger Terminal provides 8 years of financial data for Personalis, Inc. (PSNL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Personalis, Inc. (PSNL) has a book value per share of $2.92, based on its most recent annual SEC filing.